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Objectives The purpose of this study was to compare a one-time primary percutaneous coronary intervention (PCI) of the
culprit and nonculprit lesions with PCI of only the culprit lesion and staged nonculprit PCI at a later date in pa-
tients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
Background In patients with STEMI and multivessel disease, it is unknown whether it is safe or even desirable to also treat
the nonculprit vessel during the primary PCI procedure.
Methods In the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction)
trial, 668 of the 3,602 STEMI patients enrolled (18.5%) underwent PCI of culprit and nonculprit lesions for multi-
vessel disease. Patients were categorized into a single PCI strategy (n  275) versus staged PCI (n  393). The
endpoints analyzed included the 1-year rates of major adverse cardiovascular events and its components, death,
reinfarction, target-vessel revascularization for ischemia, and stroke.
Results Single versus staged PCI was associated with higher 1-year mortality (9.2% vs. 2.3%; hazard ratio [HR]: 4.1, 95% confi-
dence interval [CI]: 1.93 to 8.86, p 0.0001), cardiac mortality (6.2% vs. 2.0%; HR: 3.14, 95% CI: 1.35 to 7.27,
p 0.005), definite/probable stent thrombosis (5.7% vs. 2.3%; HR: 2.49, 95% CI: 1.09 to 5.70, p 0.02), and a trend
toward greater major adverse cardiovascular events (18.1% vs. 13.4%; HR: 1.42, 95% CI: 0.96 to 2.1, p 0.08). The mor-
tality advantage favoring staged PCI was maintained in a subgroup of patients undergoing truly elective multivessel PCI.
Also, the staged PCI strategy was independently associated with lower all-cause mortality at 30 days and at 1 year.
Conclusions A deferred angioplasty strategy of nonculprit lesions should remain the standard approach in patients with STEMI un-
dergoing primary PCI, as multivessel PCI may be associated with a greater hazard for mortality and stent thrombosis.
(Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI];
NCT00433966) (J Am Coll Cardiol 2011;58:704–11) © 2011 by the American College of Cardiology Foundation
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August 9, 2011:704–11 Multivessel Intervention in Myocardial Infarction(STEMI) (1). However, in STEMI patients, multivessel
coronary disease is often encountered and poses a therapeu-
tic dilemma, for example, whether to treat the nonculprit
lesion/vessel at the same setting. In nonshock STEMI
patients, the American College of Cardiology/American Heart
Association and European Society of Cardiology guidelines
support the use of primary PCI directed only at the
infarct-related artery, with PCI of the nonculprit lesions
guided by objective evidence of residual ischemia at later
follow-up (2,3). Since large-scale, prospective randomized
linical trials are lacking to guide the appropriateness of
omplete revascularization during the course of STEMI, it is yet
nknown whether it is safe or even desirable to also treat the
onculprit vessel during the acute infarction phase.
See page 712
The large-scale prospective HORIZONS-AMI (Har-
monizing Outcomes With Revascularization and Stents in
Acute Myocardial Infarction) trial randomly assigned
STEMI patients undergoing primary PCI to bivalirudin
alone compared to heparin plus a glycoprotein IIb/IIIa
inhibitor (GPI), and to the use of TAXUS Express
paclitaxel-eluting stents versus Express bare metal stents
(both Boston Scientific, Natick, Massachusetts) (4–6). We,
therefore, analyzed the HORIZONS-AMI database to
explore the impact of a single “1-time” intervention (PCI of
culprit and nonculprit lesions together) versus PCI of the
culprit lesion only with staged nonculprit PCI at a later date.
Methods
Study protocol. The HORIZONS-AMI study design has
been previously described in detail (4–6). In summary, the
HORIZONS-AMI study was a prospective, open-label,
randomized, multicenter trial in which 3,602 patients with
STEMI presenting within 12 h of symptom onset and
undergoing a primary PCI management strategy were ran-
domly allocated equally in the emergency department using
a computerized interactive voice response system to bivali-
rudin alone versus unfractionated heparin plus a GPI (the
control group). After angiography, eligible patients were
randomly allocated again in a 3:1 ratio to either TAXUS
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2011, accepted February 22, 2011.Express paclitaxel-eluting stents
or otherwise identical uncoated
Express bare metal stents. The
study was approved by the insti-
tutional review board or ethics
committee at each participating
center, and all patients signed
informed consent.
Patient eligibility has also been
described previously (4–6). In
summary, consecutive patients
18 years of age with symptom
onset within 12 h of duration and
ST-segment elevation of1 mm
in 2 contiguous leads, new left
bundle branch block, or true pos-
terior MI were considered for
enrollment. Principal exclusion
criteria included contraindica-
tions to any of the study medica-
tions; prior administration of fibrinolytic therapy, bivaliru-
din, GPI, low molecular weight heparin, or fondaparinux
for the present admission (prior unfractionated heparin was
allowed); current use of warfarin; history of bleeding dia-
thesis, conditions predisposing to hemorrhagic risk, or
refusal to receive blood transfusions; stroke or transient
ischemic attack within 6 months or any permanent neuro-
logic deficit; recent or known platelet count 100,000
cells/mm3 or hemoglobin 10 g/dl; planned elective surgi-
al procedure that would necessitate interruption of thien-
pyridines during the first 6 months after enrollment;
oronary stent implantation within 30 days; and noncardiac
omorbid conditions with life expectancy 1 year or that
ight result in protocol noncompliance.
Clinical follow-up was pre-specified at 30 days, at 1 year,
nd yearly thereafter for 3 years total in all patients, with the
xception of patients in whom all measured cardiac bio-
arkers were within normal limits and no coronary artery
esions were present with a diameter stenosis 50% by core
aboratory determination; these patients required only 30-
ay follow-up.
atients and study analysis. Of the 3,602 STEMI patients
nrolled in the trial, 668 patients (18.5%) underwent PCI
or multivessel coronary artery disease. Per operator discre-
ion, PCI of the nonculprit lesions and vessels could be
erformed either during the acute infarct procedure (after
uccessful treatment of the infarct-related artery), or in a
eparate staged procedure. A total of 275 patients (41%)
nderwent a 1-time multivessel procedure, whereas staging
as performed in 393 (Fig. 1A). Patients undergoing
ultivessel PCI were further stratified by excluding from
oth groups all patients in whom the second lesion was in a
essel with Thrombolysis In Myocardial Infarction (TIMI)
ow grade 0 to 2, in whom emergent nonculprit PCI might
ave been required. This latter classification thus defined 2
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
GPI  glycoprotein IIb/IIIa
inhibitor
LVEF  left ventricular
ejection fraction
MACE  major adverse
cardiovascular event(s)
NACE  net adverse
clinical event(s)
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctiontrue elective” multivessel PCI groups, namely, 165 patients
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staged elective multivessel PCI (Fig. 1B).
Study endpoints. The study endpoints for the current
analysis included the 1-year rates of major adverse cardio-
vascular event (MACE) and its components, consisting of
death, reinfarction, ischemia-driven target vessel revascular-
ization, and stroke. Stent thrombosis events were also
adjudicated. Major bleeding (not related to coronary artery
bypass graft surgery) and net adverse clinical events
(NACE), defined as major bleeding or composite MACE,
were additional pre-specified endpoints included in the
original study and reported in the current analysis. The
definitions of major bleeding and the individual component
of MACE have been previously reported (4–6). Stent
thrombosis was defined as the definite or probable occur-
rence of a stent-related thrombotic event, according to the
Academic Research Consortium classification (7). An inde-
pendent Clinical Events Committee blinded to treatment
assignment adjudicated all primary endpoint and stent
Figure 1 Study Protocol
(A) All patients undergoing multivessel primary coronary intervention (PCI) and
(B) patients with true elective multivessel PCI in the HORIZONS-AMI (Harmoniz-
ing Outcomes With Revascularization and Stents in Acute Myocardial Infarction)
trial. BMS  bare-metal stent; CAD  coronary artery disease; GP  glycopro-
tein; MV  multivessel; pts  patients; STEMI  ST-segment elevation myo-
cardial infarction; TIMI  Thrombolysis In Myocardial Infarction; UFH 
unfractionated heparin.thrombosis events using original source documents.Statistical methods. The present study represents a pre-
specified analysis from the HORIZONS-AMI trial. Cate-
gorical outcomes were compared by chi-square or Fisher’s
exact test. Continuous variables were compared by the
Wilcoxon rank-sum test. The primary event analyses were
performed using time-to-event data (for which patients
were censored at the time of withdrawal from the study or
at last follow-up), displayed using Kaplan-Meier method-
ology, and compared with the log-rank test. Cox propor-
tional hazards regression was performed to determine the
independent predictors of all-cause mortality at 30 days and
1 year. Variables were selected using a forward stepwise
algorithm with entry and stay significance levels of 0.1.
Our multivariate model tested 2 analytical methods. First,
we included in the multivariate model only selected covari-
ates that are expected to be related to long-term outcomes.
Then, to avoid an “over-fitting” problem due to relatively
large number of variables and fewer outcome events, we
used an additional propensity score model for each outcome
category that tests single versus staged PCI using only the
propensity score as a covariate. This covariate refers to a
variable for the propensity to undergo multivessel interven-
tion. It was developed using a logistic regression model and
was aimed to reduce selection bias in the elected treatment
strategy (i.e., single/deferred versus multivessel PCI strat-
egy) and its potential impact on measured outcomes.
The propensity was adjusted for age, drug-eluting stent
use, dyslipidemia, smoking history, prior coronary artery
disease or peripheral vascular disease or stroke, Killip class
2, pre-randomization heparin treatment, and clopidogrel
loading dose. Also, this method allowed us to reduce more
effectively the number of covariates when outcome event
counts were relatively low in our study. The elected variables
that were included in the original model are listed as
follows: age, sex, Killip class, anemia, creatinine clearance
60 ml/min, bivalirudin use (vs. unfractionated heparin
plus GP IIb/IIIa), history of diabetes mellitus, clopidogrel
loading dose (600 vs. 300 ng), pre-randomization heparin,
symptom to first balloon time, left anterior descending
artery disease, pre-TIMI flow grade, left ventricle ejection
fraction (LVEF), and single vessel versus multivessel PCI.
Results
Patients and procedures. The median time interval be-
tween the first and second PCI procedures in the staged
group was 30 days (range 6.0 to 51 days). The 2 groups were
well matched (Table 1). The median baseline LVEF was
not significantly different between groups, but more patients
in the single PCI arm had a left ventricular ejection fraction
40% (20.5% vs. 11.1%, p  0.002). Baseline medications
were similar between groups (data not shown). Pre-
intervention TIMI flow grade 0/1 in the culprit vessel was
more prevalent in the staged PCI group (by both operator
report and quantitative coronary angiography). The final
angiographic culprit lesion rate of TIMI flow grade 3 was
d
T
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August 9, 2011:704–11 Multivessel Intervention in Myocardial Infarctionhigh (90%) and similar between groups per operator
report, but slightly less frequent in the staged PCI group per
quantitative coronary angiography (86.7% vs. 91.7%, p 
0.02). Bivalirudin and GPI treatments were distributed
equally among groups (Table 1). However, randomization
to the TAXUS stent was more frequent in the single PCI
group versus staged PCI group (81.5% vs. 72.3%, p 
0.009).
In the 1-time group as compared to the staged PCI
group, the average number of stents implanted during the
index procedure was higher (2.2  1.1 vs. 1.7  1.0, p 
0.0001), the number of vessels treated was greater (1.5 
0.5 vs. 1.0, p  0.0001), the number of lesions treated was
greater (1.7 0.7 vs. 1.2 0.5, p 0.0001), the mean total
stent length was greater (37 mm vs. 28 mm, p  0.0001), a
greater amount of contrast was utilized (275 ml vs. 235 ml,
p  0.0001), and the mean total fluoroscopy time was
longer (16.0 min vs. 11.0 min, p  0.0001).
Clinical outcomes. Table 2 summarizes the adverse events
occurring through 1 year of follow-up for both groups. At 1
year, patients undergoing 1-time versus staged multivessel
PCI had a significantly greater rate of all-cause mortality
Baseline Characteristics,Procedures, nd Medication UseTable 1 B seline Characteristics,Procedures, and Medication Use
Single PCI
(n  275)
Staged PCI
(n  393) p Value
Mean age, yrs 62.0 63.5 0.84
Male, % 79.6 80.9 0.68
Diabetes mellitus, % 15.3 18.1 0.34
Hypertension, % 54.9 57.5 0.50
Hyperlipidemia, % 48.0 41.7 0.11
Smoking history, % 61.3 62.8 0.69
History of MI, % 9.5 7.9 0.47
History of angioplasty, % 11.3 7.9 0.14
History of bypass surgery, % 3.3 2.8 0.72
History of CHF 3.6 3.6 0.96
LAD culprit, % 40.6 35.1 0.09
Symptoms to balloon, min 232.0 229.0 0.94
Door to balloon, min 110.0 102.0 0.14
Killip class 2, % 10.6 7.1 0.11
Baseline LVEF, mean % 57.4 58.6 0.23
LVEF 40%, % 20.5 11.1 0.002
Pre-TIMI flow grade 0/1,*% 44.3 68.0 0.0001
Pre-TIMI flow grade 0/1,†% 39.4 62.2 0.0001
Post-TIMI flow grade 3,*% 93.2 92.4 0.63
Post-TIMI flow grade 3,*†% 91.7 86.7 0.02
Bivalirudin randomization, % 51.6 50.4 0.75
TAXUS stent randomization, % 81.5 72.3 0.009
Pre-randomization heparin, % 60.4 71.8 0.002
Received GPI,‡% 54.5 54.6 0.99
Aspiration catheter used, % 9.6 12.5 0.24
Thienopyridine loaded, % 99.3 99.7 0.57
*Operator report. †Quantitative coronary angiography core laboratory report. ‡Any glycoprotein
IIb/IIIa administration during and after percutaneous coronary intervention (PCI).
CHF  congestive heart failure; GPI  glycoprotein IIb/IIIa inhibitor; LAD  left anterior
escending artery; LVEF  left ventricular ejection fraction; MI  myocardial infarction; TIMI 
hrombolysis In Myocardial Infarction.(9.2% vs. 2.3%, hazard ratio [HR]: 4.10, 95% confidenceinterval [CI]: 1.93 to 8.86, p  0.0001) and cardiac
mortality (6.2% vs. 2.0%, HR: 3.14, 95% CI: 1.35 to 7.27,
p  0.005). A higher mortality rate was present at 30 days
after STEMI (all-cause mortality 5.8% vs. 1.5%, HR: 3.81,
95% CI: 1.51 to 9.62, p 0.002; and cardiac mortality 5.5%
vs. 1.5%; HR: 3.57, 95% CI: 1.40 to 9.09, p 0.004). Time
to mortality and cardiac mortality curves for patients with
multivessel PCI, distinguished by revascularization strategy,
are shown in Figure 2.
At 1 year, patients undergoing 1-time compared to staged
PCI also experienced more stent thrombosis events, espe-
cially more “definite” stent thrombosis events within the
first month after STEMI. There was no significant differ-
ence in the rate of reinfarction or target vessel revascular-
ization between groups (Table 2). The composite MACE
endpoint at 1 year (death, reinfarction, target vessel revas-
cularization for ischemia, and stroke) tended to be higher in
the 1-time PCI arm, although the overall difference did not
reach statistical significance (18.1% vs. 13.4%, p  0.08).
Major and minor bleeding complications rates were also
significantly increased in the 1-time versus staged PCI
groups according to some but not all of the definitions
(Table 2). At 30 days, NACE was significantly higher
among patients undergoing 1-time versus staged PCI
(16.0% vs. 9.7%, HR: 1.72, 95% CI: 1.12 to 2.66, p 0.01).
However, the difference in NACE between groups was
attenuated by 1 year so the difference was no longer
significant (23.5% vs. 19.2%, HR: 1.29, 95% CI: 0.92 to
1.80, p  0.14).
True elective procedures. After excluding patients in
whom the nonculprit lesions were in vessels with TIMI flow
grade 0 to 2, the 2 remaining groups (representing the “true”
elective multivessel PCI groups) were again well matched
for baseline features (data not shown), although the mean
ejection fraction was lower in the 1-time PCI group (50%
vs. 55%, p  0.01). Patients undergoing elective 1-time
multivessel PCI (n  165) compared to a staged PCI
strategy (n  77) had higher 1-year rates of all-cause
mortality (8.0% vs. 1.3%, p  0.04) and cardiac mortality
(4.9% vs. 0%, p  0.05) (Fig. 3).
Multivariable analysis. The staged versus 1-time multi-
vessel PCI strategy was independently associated with lower
all-cause mortality at 30 days and at 1 year (Table 3). The
finding of staged PCI being a predictor of reduced mortality
persisted after adjusting the model for the observed covari-
able and also using the “propensity score” as the only
covariable used in the second model (Table 3, lower part).
Additional variables that also predicted mortality were
Killip class 2 and measured creatinine clearance 60
ml/min.
Staged versus single PCI was also and independent
predictor for improved MACE at 30 days and 1 year.
Additional variable that were independently correlated with
improved composite MACE are shown in Table 3. Finally,
a strong similar trend for reduced mortality in favor of the
staged PCI approach was also present in the true elective
licable;
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CI: 0.02 to 1.11, p  0.06).
Discussion
Multivessel disease encountered during the course of
STEMI PCI poses a therapeutic dilemma (8–16). It is also
associated with an adverse prognosis among STEMI pa-
tients after primary PCI (8–16). Whether multivessel in-
tervention during the index primary PCI procedure is safe
has been the matter of debate. Some (10–12), but not all
(8,13) studies have suggested that this practice is associated
with increased mortality and reinfarction. More recently,
advances in PCI techniques and adjunctive pharmacother-
apy have led some operators and investigators to advocate a
single-setting multivessel PCI strategy during the index
STEMI procedure (8,9). The present analysis from the
large-scale, contemporary and prospective international
HORIZONS-AMI trial strongly suggests that a deferred
angioplasty strategy for nonculprit lesions should remain the
standard approach for patients with STEMI and multivessel
disease undergoing primary PCI. Compared to a staged
treatment approach, multivessel PCI that included noncul-
prit vessels during the acute STEMI reperfusion procedure
was strongly associated with a greater hazard for 1-year
Adverse Events at 1 YearTable 2 Adverse Events at 1 Year
Single PCI
(n  275)
Mortality, all causes, % 9.2
Cardiac, % 6.2
Reinfarction (Q/non-Q) 6.5
Ischemic TVR, n 8.9
Stroke, total 0.4
Stent thrombosis, n/total n
Definite 5.0
Probable 0.8
Definite or probable 5.7
Acute (0–24 h) 0.7
Acute/subacute (0–30 days) 4.8
Late (30–365 days) 0.8
MACE 18.1
NACE 23.5
Bleeding endpoints
Protocol major, non-CABG 9.5
Protocol major, all 9.5
Intracranial bleed 0
Blood transfusion 5.1
TIMI major 4.0
TIMI minor 2.5
TIMI major or minor 6.5
GUSTO LT* or severe 0.7
GUSTO moderate 4.4
GUSTO LT or severe or moderate 5.1
*Life-threatening (LT) stent thrombosis was defined according to the
CABG  cardiac artery bypass surgery; CI  confidence interval; G
Arteries; MACE  major adverse cardiovascular events; NA  not app
vessel revascularization; other abbreviations as in Table 1.all-cause mortality, cardiac mortality, MACE, and stentthrombosis. Even after multivariable correction for the
baseline and post-procedure differences between the
groups and also after using propensity score matching,
staging the intervention remained a powerful indepen-
dent predictor of enhanced survival. These findings also
persisted after excluding all patients in whom the second
nonculprit lesion was in a vessel with compromised
angiographic epicardial flow, for which PCI was arguably
“needed” during the index procedure. Thus, pending the
results of a definitive randomized trial, a multivessel PCI
strategy during the course of STEMI cannot be recom-
mended as a routine approach in patients requiring
multivessel intervention.
Our results are in accordance with the current American
College of Cardiology/American Heart Association guide-
lines, which state that elective PCI should not be performed
in a noninfarct-related artery at the time of primary PCI of
the infarct-related artery in patients without hemodynamic
compromise (Class IIIc indication) (2). Similarly, the Eu-
ropean Cardiology Society guidelines state that in patients
with multivessel disease, primary PCI should be directed
only at the infarct-related artery; decisions about PCI on
nonculprit lesions should be guided by objective evidence of
residual ischemia at later follow-up (3). Notably, those
Staged PCI
(n  393) RR (95% CI) p Value
2.3 4.10 (1.93–8.86) 0.0001
2.0 3.14 (1.35–7.27) 0.005
4.7 1.43 (0.73–2.77) 0.29
8.1 1.13 (0.66–1.93) 0.66
0.8 0.51 (0.05–4.89) 0.55
1.6 3.24 (1.23–8.54) 0.01
0.8 0.99 (0.16–5.90) 0.99
2.3 2.49 (1.09–5.70) 0.02
1.0 0.72 (0.13–3.88) 0.99
1.8 2.66 (1.07–6.58) 0.03
0.5 1.53 (0.22–10.9) 0.67
13.4 1.42 (0.96–2.1) 0.08
19.2 1.29 (0.92–1.80) 0.14
6.9 1.38 (0.82–2.31) 0.22
7.1 1.33 (0.80–2.21) 0.23
0 NA NA
1.5 3.33 (1.30–8.57) 0.008
1.3 3.14 (1.10–8.95) 0.02
5.1 0.50 (0.21–1.17) 0.10
6.4 1.03 (0.57–1.85) 0.92
0.3 2.86 (0.26–1.36) 0.57
1.3 3.43 (1.22–9.62) 0.01
1.5 3.33 (1.30–8.57) 0.008
ic Research Consortium classification.
Global Utilization of Streptokinase and t-PA for Occluded Coronary
NACE  net adverse clinical events; RR  relative risk; TVR  targetAcadem
USTO recommendations were based on relatively small observa-
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largest PCI trials performed up to date provides important
complementary and supportive data to the existing literature
on which these guidelines are based.
The reasons why multivessel intervention during the
index primary PCI procedure may not be safe are unknown,
but are likely multifactorial. Any PCI procedure is challeng-
ing in the setting of hemodynamic instability and left
ventricular dysfunction. The prothrombotic and inflamma-
tory milieu in the early phase of STEMI may also increase
procedural risks (17–19). Consistent with this mechanism,
the incidence of stent thrombosis in the present study was
increased in patients undergoing a single setting rather than
staged multivessel intervention. Second, lesion severity in
nonculprit vessels can be overestimated at the time of
primary PCI because of diffuse coronary vasoconstriction
and systemic endothelial dysfunction (20); rarely are non-
Figure 2 Clinical Outcomes of Patients With
Multivessel Disease
One-year clinical outcomes of all patients with multivessel disease undergoing
culprit and nonculprit lesion intervention according to 1-time (solid lines) ver-
sus staged (dashed lines) revascularization strategy. (A) Time to mortality.
(B) Cardiac mortality.invasive testing data available or the time taken to performfractional flow reserve in this setting to guide multivessel
intervention. Third, multivessel PCI increases contrast use,
which may be less well tolerated in the patient with
STEMI, especially if radiocontrast nephropathy develops
(21). Finally, unforeseen periprocedural complications in
the nonculprit vessel may be poorly tolerated due to the
“double jeopardy” of large myocardial territories at risk (i.e.,
simultaneous impairment of the culprit and nonculprit
regions).
Conversely, there are numerous reasons why multivessel
PCI during the index procedure may be desirable. Plaque
instability may not be limited to culprit lesions, and may
result in recurrent ischemia and infarction (22). The
SWISSI II (Swiss Interventional Study on Silent Ischemia
Type II) randomized trial demonstrated that the presence of
silent ischemia after AMI is associated with a significantly
higher rate of cardiac death and major adverse events if not
treated (14). Complete coronary revascularization has been
associated with a better long-term cardiac prognosis and
Figure 3 Clinical Outcomes of True Elective
PCI-Treated Patients
One-year clinical outcomes among true elective multivessel primary coronary
intervention (PCI)-treated patients according to 1-time (solid lines) versus
staged (dashed lines) revascularization strategy. (A) Time to mortality.
(B) Cardiac mortality.
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PCI strategy may be cost saving, and decrease the need
for future hospitalizations and procedures. It is possible
that the findings from the present and previous nonran-
domized studies are due to selection bias and the presence
of unmeasured confounders in the single-setting multi-
vessel PCI group that necessitated earlier nonculprit
intervention.
To address these issues, 2 small randomized trials have
recently been performed. Politi et al. (23) assigned 214
STEMI patients with multivessel disease to culprit-
lesion only PCI, 1-time multivessel PCI, or staged
multivessel PCI treatment (23). In-hospital death, repeat
revascularization, and rehospitalization occurred more
frequently in the culprit-lesion angioplasty group (all p 
0.05). However, after a mean follow-up period of 2.5
years, there were no significant differences among the 3
Multivariable Predictors of30-Day and 1-Year M tality and MACETable 3 Multivariable Predictors of30-Day and 1-Year Mortality and MACE
HR (95% CI) p Value
Original model
Predictors of mortality (30 days)
Staged PCI (vs. single) 0.33 (0.11–0.94] 0.0388
Killip class 2 3.74 (1.27–11.03) 0.017
Creatinine clearance 60 ml/min 4.18 (1.54–11.33) 0.005
Predictors of mortality (1 yr)
Staged PCI (vs. single) 0.30 (0.12–0.73) 0.0083
Killip class 2 3.02 (1.17–7.79) 0.022
Creatinine clearance 60 ml/min 4.91 (2.15–11.23) 0.0002
Predictors of MACE (30 days)
Staged PCI (vs. single) 0.41 (0.19–0.89) 0.0248
Killip class 2 4.02 (1.67–9.69) 0.0019
Creatinine clearance 60 ml/min 2.13 (0.95–4.79) 0.0666
Baseline TIMI flow grade 0/1 4.12 (1.41–12.05) 0.0098
Predictors of MACE (1 yr)
Staged PCI (vs. single) 0.53 (0.33–0.86) 0.01
History of diabetes mellitus 1.95 (1.12–3.37) 0.0173
Killip class 2 2.27 (1.17–4.38) 0.0148
Creatinine clearance 60 ml/min 1.79 (1.04–3.08) 0.0363
LAD disease 3.17 (1.15–8.75) 0.0262
Baseline TIMI flow grade 0/1 1.91 (1.10–3.30) 0.0212
LVEF (10% decrease) 1.24 (1.02–1.50) 0.03
Propensity score model
Predictors of mortality (30 days)
Staged PCI (vs. single) 0.31 (0.12–0.81) 0.0164
Propensity score 0.02 (0.00–0.86) 0.0416
Predictors of mortality (1 yr)
Staged PCI (vs. single) 0.27 (0.13–0.60) 0.0011
Propensity score 0.04 (0.00–0.86) 0.0402
Predictors of MACE (30 days)
Staged PCI (vs. single) 0.44 (0.23–0.84) 0.0127
Propensity score 0.05 (0.00–0.93) 0.0446
Predictors of MACE (1 yr)
Staged PCI (vs. single) 0.71 (0.48–1.06) 0.0941
Propensity score 0.30 (0.05–1.96) 0.2082
HR  hazard ratio; other abbreviations as in Tables 1 and 2.groups in terms of death or MI. The HELP-AMI(Hepacoat for Culprit or Multivessel Stenting for Acute
Myocardial Infarction) study was a small multicenter
randomized study (n  69) that performed an unbalanced
randomization and compared culprit lesion treatment
only (n  17) to complete “1-time” multivessel PCI (n 
52) during STEMI (11). The study found the 1-time
multivessel strategy was safe but not necessarily justified
based on subsequent need for clinically driven revascu-
larization procedures and/or economical considerations.
However, both trials were under-powered for the end-
points examined. The APEX-AMI (Assessment of
Pexelizumab in Acute Myocardial Infarction) trial was
designed to explore the incidence of and propensity for
nonculprit interventions performed at the time of the
primary PCI and its association with 90-day outcomes
(24). Of the 5,373 patients who underwent primary PCI
in this analysis, 2,201 had multivessel disease, and of
those, only 217 (9.9%) underwent noninfarct-related
arteries PCI. Ninety-day death and death/heart failure/
shock were higher in the noninfarct-related group com-
pared with the culprit only PCI group (12.5% vs. 5.6%,
p  0.001, and 17.4% vs. 12.0%, p  0.020, respectively).
After adjusting for patient and procedural characteristics
as well as propensity for performing nonculprit PCI, this
procedure remained independently associated with an
increased hazard of 90-day mortality (adjusted HR: 2.44,
p  0.001). In addition, analysis of 1,598 patients enrolled in
the EUROTRANSFER Registry database showed that in
STEMI patients treated using emergent PCI, multivessel
disease was identified as an independent predictor of 1-year
death (25). In 70 patients (9%), nonculprit PCI was
performed during the index PCI. These patients were at
higher risk of 30-day and 1-year death compared to patients
with culprit only PCI. However, this difference in mortality
was no longer significant after adjustment for covariates.
Study limitations. In addition to the issue of residual
confounding, several limitations of the present analysis
warrant discussion: 1) although pre-specified, the present
study is a retrospective nonrandomized subanalysis from a
pivotal prospective randomized trial; 2) the cohort of 668
patients with STEMI undergoing multivessel PCI (41%
during the index procedure) may still be under-powered to
assess subtle distinctions between the 2 strategies; and 3) the
specific reasons why operators chose a single procedure
versus a staged approach was not prospectively collected.
Despite our efforts to eliminate bias due to the nonrandom-
ized nature of the comparison, we cannot totally refute the
possibility that such bias actually existed and was not
identified or eliminated in our careful statistical model.
We have made our best attempt to reduce the impact of
treatment bias by adding the propensity score covariate to
the multivariate model. Although the event count was
relatively low, findings remained with propensity score
adjustment. Thus, the likelihood of a bias effect to
explain our results is small.
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These limitations notwithstanding, the results of the present
study clearly suggest that a routine emergent multivessel
PCI during the course of STEMI should be strongly
discouraged. This is because it is associated with a greater
hazard for subsequent mortality, stent thrombosis, and
MACE in comparison to a staged PCI strategy. In the
present analysis, we could not determine or compare the
culprit vessel versus the nonculprit vessel PCI as this
information has not been systematically recorded in the
HORIZONS database. Thus, in summary, pending the
results of a properly designed randomized trial, a deferred
angioplasty strategy of nonculprit lesions should remain the
standard approach to patients with STEMI and multivessel
coronary artery disease.
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